Johnson & Johnson Innovation last year launched JLINX to identify and nurture early stage companies with the potential to transform human health. Launched in partnership with Bioqube Ventures and located on the Janssen R&D Campus in Beerse Belgium, JLINX offers startups a spectrum of flexible resources and approaches to grow and collaborate across the European life science ecosystem.
One of the first resident companies unveiled by JLINX is S-Biomedic, which is focused on the microbiome-based solutions for skin care. S-Biomedic has developed a method to directly modulate the skin microbiome with applications in dermatology and the cosmetic industry. Johnson & Johnson Innovation – JJDC, Inc. (JJDC) has invested in S-Biomedic and the company will become a member of the JLINX community, according to the company.
In addition, J&J’s famed baby care line is developing whatit calls "the first personalized baby sleep coaching system". Johnson & Johnson Consumer Inc., through its Johnson’s Bedtime Baby Sleep App, and Rest Devices, Inc., through the Mimo Baby wearable monitor, have each studied sleep patterns for hundreds of thousands of babies. The companies have formed a collaboration to combine expert coaching and analytics into one app, called Nod, providing parents with an advanced sleep coaching system that helps babies sleep more soundly. Nod will be released in February 2017.
"We continue to pursue transformative healthcare solutions and form collaborations that explore the cutting edge of scientific research to achieve our primary goal of improving the quality of patients' lives," said Paul Stoffels, M.D., CSO, Johnson & Johnson. "Through Johnson & Johnson Innovation, we are committed to identifying and advancing novel solutions in areas of significant need and creating customized deal structures with innovators in an effort to accelerate products to market."